FDA Approves BUPRENORPHINE — Hikma Pharmaceuticals USA Inc.

Hikma Pharmaceuticals USA Inc. has successfully won approval for a supplementary new drug application to manufacture and market bucinoroxine hydrochloride in the sublingual route, following an ANDA originally filed in 2009. This authorization bolsters Hikma’s portfolio by expanding its presence in the critical opioid addiction treatment market, providing a competing generic alternative to long-standing brand names.